Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study - Poll - MDSpire

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

  • By

  • Simran Chandra

  • Sagar Hansraj

  • Aakriti Adhikari

  • Ben Ponvilawan

  • Addison Tolentino

  • Dhruv Bansal

  • April 27, 2026

  • 0 min

Share

Original Source(s)

Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

  • by Simran Chandra, Sagar Hansraj, Aakriti Adhikari, Ben Ponvilawan, Addison Tolentino, Dhruv Bansal

  • April 27, 2026

Related Content

High-grade astrocytoma with piloid features: a case report of comprehensive management

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer